~ Un-Common Sense In An Irrational World: We Challenge the Conventional WisdomTM ~
📢 Final chance to join Trethera live: Don’t miss Trethera’s last investor webinar before the Seed Round closes Sept 30 — happening Tuesday, Sept 9 at 2 PM PT.
In case you missed it — Trethera recently secured $5.3M in non-dilutive NIH funding to advance their clinical-stage drug TRE-515 across two important programs:
$2.3M award supporting TRE-515 in combination with radiation therapy for prostate cancer ➡️ Read more: Trethera Awarded $2.3 Million NIH Grant to Study TRE-515 Combined with Radiation Therapy in Prostate Cancer Preclinical Models | Trethera
$3M award advancing TRE-515 as a potential treatment for lupus ➡️ Read more: Trethera Awarded $3 Million NIH Grant to Advance First-In-Class Drug, TRE-515, for the Treatment of Lupus | Trethera
These grants highlight the broad therapeutic potential of TRE-515, a single oral agent being advanced across both oncology and autoimmune indications.
📩 Receive an invitation here: Webinar Registration – Zoom